CLEO Enters Analytical Validation Phase
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced that it is entering the analytical validation phase for its ovarian cancer test kits, following the completion of commercial assay development. This milestone is part of the company's preparations for a planned FDA submission, expected to occur in the first half of the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Appendix 4D and Half Yearly Accounts
Later from CLEO Diagnostics
- Appendix 4E and 2026 Annual Report
- CLEO Receives First Batch of Commercial Test Kits
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- CLEO Commences Ovarian Cancer Screening Test Development
- Cleo Files Patents for its Ovarian Cancer Screening Test
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics